Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGN-EDODM1 Open-Label Extension in Myotonic Dystrophy Type 1
NCT07220603Phase 2Recruiting
- Sponsor
- PepGen
- Start
- Dec 2025
- Primary completion
- Jan 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of PGN-EDODM1 in myotonic dystrophy type 1 (DM1), sponsored by PepGen. Started Dec 2025; status: recruiting.
02
Drugs
PGN-EDODM1
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT07220603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220603.